Sanjoinine A Isolated from Zizyphi Spinosi Semen Augments Pentobarbital-Induced Sleeping Behaviors through the Modification of GABA-ergic Systems
Zizyphi Spinosi Semen (ZSS) has been widely used for the treatment of insomnia in oriental countries. This experiment was performed to investigate whether sanjoinine A, one of major alkaloid compounds of ZSS, has hypnotic effects and/or enhances pentobarbital-induced sleeping behaviors through the g g-aminobutyric acid (GABA)-ergic systems. Sanjoinine A itself did not induce sleeping at the higher dose used in this experiment. However, sanjoinine A prolonged sleeping time and reduced the sleeping latency induced by pentobarbital in a dose-dependent manner similar to muscimol, a GABA A receptor agonist. Sanjoinine A also increased sleeping rate and sleeping time when administered combined with pentobarbital at a sub-hypnotic dosage and showed synergistic effects with muscimol in potentiating sleeping onset and enhancing sleeping time induced by pentobarbital. In addition, both sanjoinine A and pentobarbital increased chloride influx in primary cultured cerebellar granule cells. Sanjoinine A also showed similar effects with muscimol in potentiating chloride influx inducing effects of low dose pentobarbital. Sanjoinine A decreased GABA A receptor a a-subunit expression and increased g g-subunit expression, and had no effects on the abundance of b b-subunits in primary cultured cerebellar granule cells, showing different subunit expression from pentobarbital. In addition, we found that sanjoinine A also enhanced expression of glutamic acid decarboxylase (GAD), but pentobarbital did not. In conclusion, sanjoinine A itself does not induce sleeping, but it augments pentobarbital-induced sleeping behaviors through the modification of GABA-ergic systems.
hydrochloric acid (60 ml) and ether (50 ml). This aqueous acid solution was extracted three times more with ammonia hydrate (pH 9.0) and chloroform (60 mlϫ3). The alkaloid fractions in chloroform solution were combined, filtered through Whatman No. 1 filter paper, and concentrated using a rotary vacuum evaporator followed by lyophilization. The yield of the alkaloid fraction was about 0.03% (w/w). 4) Using combined flash column chromatography and preparative thin layer chromatography, fourteen alkaloids were isolated in a crystalline state from the alkaloid fraction of ZSS. The alkaloids were labeled as Sanjoinine-A, B, C, etc. in the order of increasing polarity. The isolation yields were highly varied ranging from 1.4ϫ10 Ϫ3 to 5ϫ10
Ϫ3
%. The chemical structures of sanjoinine A were established by a combination of chemical correlation methods and spectral analysis (Fig. 1) . 19) Pentobarbital-Induced Sleeping Pentobarbital sodium (Hanlim Pharm. Co., Ltd., Korea) was diluted in physiological saline and administered to each mouse intraperitoneally (i.p.) to induce sleep. Test samples suspended in 1% CMC in physiological saline were administered orally (p.o.) to animals (10 ml/kg). 10-15 mice were used for each treatment group. Muscimol (Sigma, U.S.A.) was administered as a reference drug 15 min prior to administration of pentobarbital. All experiments were carried out between 1:00 and 5:00 pm. Animals were fasted for 24 h prior to the experiment. Pentobarbital was given to animals placed in a box 30 min after the oral administration of test samples. Those animals that stopped moving in the box within 15 min after pentobarbital injection were immediately transferred to another box. Those individuals that stayed immobile for more than 3 min were judged to be asleep. The time that elapsed from receiving pentobarbital until an animal, positioned delicately on its back, lost its righting reflex represented the latency to onset of sleep. The animals were observed constantly, and the time of awakening, characterized by righting of the animal, was noted. The sleeping time was defined as the time taken for the animal to regain spontaneous movements after having been transferred to the second box. Animals that failed to fall asleep within 15 min after pentobarbital administration were excluded from the experiments. 20, 21) Cell Culture Primary cultures of cerebellar neurons enriched in granule cells were prepared from cerebella of 8 d old Sprague-Dawley rats (Samtako, Korea) as previously described. 22) After culture for 8 d, these cells express functional GABA A receptors, with an expression pattern similar to that apparent in the cerebellum during postnatal development but different from that observed in the adult rat cerebellum. Briefly, cells were plated (1ϫ10 6 cells per 0.2 ml) in 96 microplates or (2ϫ10 6 cells per 2.0 ml) in 60-mm dishes that had been coated with poly-D-lysine (10 mg/ml) (Sigma, U.S.A.). The cells were cultured in basal Eagle's medium (Life Technologies, U.S.A.) supplemented with 10% heatinactivated fetal bovine serum (Gibco-BRL, U.S.A.), 2.0 mM glutamine, gentamicin (100 mg/ml), antibiotic-antimycotic solution (100 unit/ml; Sigma, U.S.A.) and 25 mM KCl. This high concentration of potassium was necessary to induce persistent depolarization, which promotes the survival of granule cells. Cytosine arabinofuranoside (10 mM final concentration; Sigma, U.S.A.) was added to cultures 18-24 h after plating to inhibit the proliferation of nonneuronal cells.
Measurement of Intracellular Cl
؊ Influx The intracellular Cl Ϫ concentration of cerebellar granule cells was estimated using the Cl Ϫ sensitive fluorescence probe MQAE according to the method of West and Molloy with a slight modification.
23) The buffer (pH 7.4) used contained the following: 2.4 mM HPO . The blots were blocked for 2 h at room temperature with 5% (w/v) non-fat dried milk in Tris-buffered saline solution (10 mM Tris, pH 8.0 and 150 mM NaCl) containing 0.05% Tween-20. The membrane was incubated with the specific rabbit polyclonal antibodies against GABA A receptor subunits (1 : 500; Santa Cruz Biotechnology Inc.) or GAD65/ 67, for 6 h at room temperature. The blot was then incubated with the corresponding conjugated anti-rabbit immunoglobulin G-horseradish peroxidase (Santa Cruz Biotechnology Inc.). The immunoreactive proteins were detected using the ECL Western blotting detection system.
Statistical Analysis
The results are presented as the meanϮS.E.M. The significance of the effects of the compounds was assessed using analysis of variance (ANOVA). In case of significant variation, the individual values were compared with Dunnett's test. For the sub-hypnotic dosage of pentobarbital-treated experiment, a Chi-square test was used to compare the proportions of sleep onset between subhypnotic pentobarbital alone-treated group and each of the other groups.
RESULTS
Hypnotic Effects of Pentobarbital, Muscimol and Sanjoinine A Pentobarbital induced sleeping in a dose dependant manner. We investigated the hypnotic effects of muscimol and different doses of sanjoinine A in rodents without pentobarbital treatment, and found that sanjoinine A alone could not induce sleeping even at a very high dose (100 mg/kg). These results were similar to those of muscimol ( Table 1) .
Effects of Sanjoinine A on Sleeping Onset of Mice Treated by a Sub-hypnotic Dosage of Pentobarbital Sanjoinine A increased the rate of sleep onset and the duration of sleeping time induced by a sub-hypnotic dosage of pentobarbital (28 mg/kg. i.p.). Pretreatment with muscimol also increased the rate of sleep onset and prolonged the sleep time due to a sub-hypnotic dosage of pentobarbital (Table 2 ). It was found that sanjoinine A had similar effects to muscimol on sleeping behavior induced by pentobarbital in both experiments.
Enhancement of Sanjoinine A of the Latency and Duration of Sleeping in Pentobarbital-Treated Mice Sanjoinine A decreased the latency of sleep and increased sleeping time induced by pentobarbital (42 mg/kg) in a dose-dependent manner. Pretreatment in mice with muscimol (0.2 mg/kg i.p.) as a positive control 15 min before the administration of pentobarbital also decreased the latency of sleep and increased the total sleeping time (Fig. 2) .
Synergistic Effects of Sanjoinine A with Muscimol on Sleeping in Pentobarbital-Treated Mice To investigate the direct relationship between the effects of muscimol and sanjoinine A, sanjoinine A (0.5 mg/kg)-treated groups were pretreated with low doses of muscimol (0.05 mg/kg), which did not potentiate sleeping induced by pentobarbital. Muscimol and sanjoinine A alone did not affect the sleeping time induced by a hypnotic dosage of pentobarbital. However, co-administration of muscimol (0.05 mg/kg) significantly decreased sleep latency and increased sleeping time induced by pentobarbital in the sanjoinine A (0.5 mg/kg)-treated groups (Fig. 3) .
Increase 
Fig. 3. Synergistic Effects of Sanjoinine A on Sleeping in PentobarbitalTreated Mice
Mice were fasted for 24 h before the experiment. After administration of muscimol and tested drugs, pentobarbital (42 mg/kg) was given i.p. to mice. The sleep latency (A) and sleeping time (B) were recorded. Each column represents the mean plus S.E.M. * * pϽ0.01, compared to that of the control group.
Fig. 2. Effects of Sanjoinine A on Onset and Duration of Sleeping in Pentobarbital-Treated Mice
Mice were fasted for 24 h before the experiment. After administration of muscimol and tested drugs, pentobarbital (42 mg/kg) was given i.p. to mice. The sleep latency (A) and sleeping time (B) were recorded. Each column represents the mean plus S.E.M.
* pϽ0.05, * * pϽ0.01, compared to that of the control group.
ated effects of 2.5 mM pentobarbital, which did not potentiate Cl Ϫ influx also, in increasing the influx of Cl Ϫ . Similarly, cotreatment of muscimol (20 mM) and pentobarbital (2.5 mM) significantly increased Cl Ϫ influx in primary cultured cerebellar granule cells (Fig. 4) .
Expression of GAD65/67 by Pentobarbital and Sanjoinine A The effects of treatment of cerebellar granule cells for 5 d with 2.5 mM sanjoinine A or 10 mM pentobarbital on the abundance of GAD were examined. Chronic treatment of pentobarbital showed no effect on the abundance of GAD, treatment of sanjoinine A enhanced the amount of the GAD significantly in cultured cerebellar granule cells (Fig. 5) .
Subunits Expression of GABA A Receptors by Pentobarbital and Sanjoinine A GABA A subunits expression was examined after treatment with 2.5 mM sanjoinine A or 10 mM pentobarbital in the cerebellar granule cells for 5 d. Sanjoinine A treatment induced a significant decrease in the amount of the a-subunit and increase in g-subunit, but had no effect on the abundance of the b subunit. The amounts of a-subunit were reduced by chronic pentobarbital treatment (Fig. 6 ).
DISCUSSION
We investigated the effects of different doses of sanjoinine A, one of alkaloids from ZSS, and muscimol in rodents without pentobarbital treatment. Sanjoinine A alone could not induce sleeping even at a very high dose. These results were similar to those of muscimol. In addition, sanjoinine A increased the rate of sleep onset and the duration of sleeping time induced by sub-hypnotic dosage of pentobarbital. Changes in pentobarbital-induced sleep time can be a useful tool for examining stimulatory or inhibitory effects on the CNS, in particular for investigating influences on the GABAergic system. 24) Barbiturates interact with GABA receptors and modulate GABA-ergic effects. 25, 26) Many hypnotic, antianxiety and anti-epilepsy drugs prolong pentobarbitalinduced sleeping time. We were interested in whether sanjoinine A prolonged pentobarbital-induced sleeping behaviors via the GABA-ergic systems. It has been reported that alkaloids from ZSS have sedative effects. 16, 17, 27) The present study showed that administration of sanjoinine A prior to pentobarbital injection was associated with a statistically significant decrease of sleep latency and prolongation of pentobarbital-induced sleeping time. Therefore, we suggest that the sanjoinine A may play an important role in the hypnotic effect of ZSS. Musicimol, a standard GABA A receptors agonist, also potentiated the onset and prolonged the sleeping time in mice. Furthermore, sanjoinine A showed synergistic effects with muscimol in pentobarbital-treated mice. This indicates the involvement of the GABA receptor complex.
GABA A receptors possess different binding sites such as GABA, benzodiazepine and barbiturate. GABA A receptors form heteromeric GABA-gated chloride channels are assembled from a large family of subunit genes. GABA A receptor channels open after binding GABA to give a net inward flux of negative chloride ions (outward current), hyperpolarizing the membrane and reducing neuronal firing. 28, 29) The pharmacological profile of a GABA A receptor depends upon subunit composition, and distinct GABA A receptor subtypes differ in subunit composition. Sanjoinine A alone could not induce sleep but enhanced pentobarbital-induced sleeping. This suggests that there are differences between sanjoinine A and pentobarbital in their pharmacological properties on GABA A receptors. Sanjoinine A in combination with muscimol showed synergistic effects on pentobarbital-induced sleeping and increased Cl Ϫ influx in a similar way as pento- barbital, sanjoinine A also showed similar effects with muscimol in potentiating Cl Ϫ influx inducing effects of low dose pentobarbital. This indicated that sanjoinine A might act on functions of GABA receptor to induce Cl Ϫ channel opening, and modulate pentobarbital-induced pharmacological properties like a GABA receptor agonist. Because the activation of glycine receptors also increase chloride ion channels open that facilitate inhibitory neurotransmission in the mammalian in brain, it is also possible that sanjoinine A might increase Cl Ϫ influx by glycine receptors. 30, 31) We tried to find out the typical responding subunits of the effective dosage of sanjoinine A, which might have at least a close relationship with the acting site by which sanjoinine A acts on GABA A receptors and exerts its sleeping potentiating effects. We also investigated the effects of sanjoinine A and pentobarbital on expression of GAD65/67 expression by western blot technique. GAD65/67, which is necessary for GABA synthesis, plays a major role in GABA transmission in normal physiological condition. Sanjoinine A increased the GAD expression significantly in cultured cerebellar granule cells. It is suggested that sanjoinine A might activate GAD, then increase GABA transmission.
On the other hand, variations in GABA A receptor subunit composition confer unique pharmacological, biophysical, and electrophysiological properties to each receptor subtype and most native GABA A receptors are composed of two a, two b and a g subunit. 32) Evidence suggests that subunit composition may determine the pharmacology of GABA A receptors. 32) The importance of subunit composition is reflected in recent evidence from mutant mouse literature suggesting that different GABA A receptor subunits modulate different drug-induced behaviors. 33) Multiple compounds (GABA, benzodiazepines, barbiturates, alcohol, neurosteroids, etc.) act at different sites of the GABA/benzodiazepine receptor-chloride channel complex to increase the opening of the channel, and hence enhance inhibitory synaptic transmission.
34) The presence of any one of them influences the binding of the others. For example, barbiturates will bind more strongly to the receptor when GABA also is bound. Drugs that bind to the barbiturate site along with benzodiazepines and neurosteroids, act as allosteric modulators to enhance neuronal inhibition and result in sleep consolidation. We found that both sanjoinine A and pentobarbital decreased the abundance of the GABA A receptor a-subunit, but only sanjoinine A increased the abundance of the g-subunit. These different changes may be of the explanations for its different drug-induced sleeping behaviors. 33) Many herbal preparations and a rich chemical diversity of agents used to promote sleep is known acting on GABA A receptor. 35, 36) Agents acting on GABA A receptors mainly act to increase synaptic inhibition either by directly activating GABA A receptors or, more usually, by enhancing the action of ligands on GABA A receptors. This latter action is known as positive modulation and is considered to involve agents acting on allosteric sites on GABA A receptors remote from the traditional ligand recognition sites. 37) There is a significant diversity of GABA A receptor subtypes composed of different protein subunits. The discovery of subtype specific agents is a major challenge in the continuing development of GABA A receptor pharmacology and such allosteric sites are regarded as good targets for the development of subtype specific drugs. 38) Our results suggested that sanjoinine A might exert its sleeping potentiating effects by three pathways; 1st, increase GABA synthesis by GAD activation; 2nd, increase sensitivity of GABA receptor to pentobarbital or GABA by influence GABA receptor subunit compositions, especially by increasing g subunit expression; 3rd, it is also possible that sanjoinine A activate GABA receptors directly. A considerable number of herbal constituents whose behavioral effects and pharmacological actions have been well characterized may be good candidates for further investigations that may ultimately lead to clinical use. An increasing number of herbal products have been introduced into psychiatric practice in the past decade. The potential benefits of herbal remedies such as St. John's wort and kava-kava in psychiatric practice have been addressed. 39) ZSS might be another good candidate for use in psychiatric illnesses such as sleeping disorders.
In conclusion, all the data presented here indicate that the sanjoinine A itself did not induce sleeping and only enhanced hypnotic effects in pentobarbital-treated mice. The GABA receptor-chloride channel complex might be involved in the mechanisms of these effects. It is also suggested that pentobarbital and sanjoinine A acts on GABA receptors pharmacologically differently. Further investigation is needed in order to understand the pharmacological actions of sanjoinine A.
